Quantumup
Nov 5, 1:38 PM
TD Cowen⬆️
$ARQT's PT to
$40 from
$35 and reiterated at Buy after the Co. reported its earnings.
[ROIV
$INCY PFE AMGN ABBV JNJ UCBJY BMY OGN SNY - REGN NVS]
Here's what TD Cowen said in its note: Zoryve sales of
$144MM were roughly in-line with cons, driven by broad-based demand growth across the cream and foam, with revenue up 11% Q/Q and 45% Y/Y.
2026 guidance was raised to
$535-545MM reflecting sustained momentum as GTN improves modestly.
Near-term upside centers on YE vitiligo Phase II data, where a faster onset, QD dosing, and no boxed warning could differentiate Zoryve from Opzelura.
